CBER’s New Director “Marks” A New Era For Biologics Regulation
This article was originally published in RPM Report
Peter Marks takes over the top spot in the center for biologics at FDA after a four year training period as deputy director. His background appears well suited to what promises to be a transformative era in medicine.
Register for our free email digests: